PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.
“Restore human gut health with GaRP”
Please open the attached PDF to view the report.
PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.
“Restore human gut health with GaRP”
Please open the attached PDF to view the report.